When someone is experiencing an acute schizophrenic episode, active psychotic symptoms can be frightening. It can be ...

The acute phase of schizophrenia is the florid psychotic phase, during which the patient exhibits acute symptoms--for example, severe delusions and/or hallucinations (positive symptoms ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Besides, slower dose titration in an acute schizophrenic episode may lead to attenuated efficacy. Therefore, the convenient dosage regimen and rapid initiation scheme of quetiapine extended ...

The investigational combination xanomeline-trospium (KarXT) was effective and well tolerated in individuals with schizophrenia who were experiencing acute psychosis, according to the randomized ...

AbbVie’s (ABBV) two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with ...

The Chicago-based firm earlier announced that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral ...

Schizophrenia is a mental health disorder that causes changes to the way a person thinks, acts, and behaves. People with schizophrenia may have hallucinations, delusions, disorganized behavior ...

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...